Surveillance for Adverse Events After COVID-19 mRNA Vaccination
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Importance: Safety surveillance of vaccines against COVID-19 is critical to ensure safety, maintain trust, and inform policy. Objectives: To monitor 23 serious outcomes weekly, using comprehensive health records on a diverse population. Design, Setting, and Participants: This study represents an interim analysis of safety surveillance data from Vaccine Safety Datalink. The 10 162 227 vaccine-eligible members of 8 participating US health plans were monitored with administrative data updated weekly and supplemented with medical record review for selected outcomes from December 14, 2020, through June 26, 2021. Exposures: Receipt of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccination, with a risk interval of 21 days for individuals after vaccine dose 1 or 2 compared with an interval of 22 to 42 days for similar individuals after vaccine dose 1 or 2. Main Outcomes and Measures: Incidence of serious outcomes, including acute myocardial infarction, Bell palsy, cerebral venous sinus thrombosis, Guillain-Barré syndrome, myocarditis/pericarditis, pulmonary embolism, stroke, and thrombosis with thrombocytopenia syndrome. Incidence of events that occurred among vaccine recipients 1 to 21 days after either dose 1 or 2 of a messenger RNA (mRNA) vaccine was compared with that of vaccinated concurrent comparators who, on the same calendar day, had received their most recent dose 22 to 42 days earlier. Rate ratios (RRs) were estimated by Poisson regression, adjusted for age, sex, race and ethnicity, health plan, and calendar day. For a signal, a 1-sided P < .0048 was required to keep type I error below .05 during 2 years of weekly analyses. For 4 additional outcomes, including anaphylaxis, only descriptive analyses were conducted. Results: A total of 11 845 128 doses of mRNA vaccines (57% BNT162b2; 6 175 813 first doses and 5 669 315 second doses) were administered to 6.2 million individuals (mean age, 49 years; 54% female individuals). The incidence of events per 1 000 000 person-years during the risk vs comparison intervals for ischemic stroke was 1612 vs 1781 (RR, 0.97; 95% CI, 0.87-1.08); for appendicitis, 1179 vs 1345 (RR, 0.82; 95% CI, 0.73-0.93); and for acute myocardial infarction, 935 vs 1030 (RR, 1.02; 95% CI, 0.89-1.18). No vaccine-outcome association met the prespecified requirement for a signal. Incidence of confirmed anaphylaxis was 4.8 (95% CI, 3.2-6.9) per million doses of BNT162b2 and 5.1 (95% CI, 3.3-7.6) per million doses of mRNA-1273. Conclusions and Relevance: In interim analyses of surveillance of mRNA COVID-19 vaccines, incidence of selected serious outcomes was not significantly higher 1 to 21 days postvaccination compared with 22 to 42 days postvaccination. While CIs were wide for many outcomes, surveillance is ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×
“coagulation, multisystem inflammatory syndrome in children and adults, myocarditis/pericarditis, pulmonary embolism, stroke [hemorrhagic and ischemic], thrombotic thrombocytopenic purpura, and venous thromboembolism); or (4) emerging concerns that have arisen during the course of surveillance (cerebral venous sinus th…”
BackgroundCenters for Disease Control and Prevention
(2007) · Encyclopedia of Measurement and Statistics · doi:10.4135/9781412952644.n74 · Cited by 6,444
Group sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Spatial disease clusters: Detection and inference
Kulldorff, M., & Nagarwalla, N. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140809 · Cited by 1,599
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Higgins (2002) · doi:10.1002/(issn)1097-0258 · Cited by 1,248
Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M., Curran, K. G., Chamberland, M., McClung, N., Campos-Outcalt, D., Morgan, R. L., Mbaeyi, S., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6950e2 · Cited by 536
CDC COVID-19 Response Team, & Administration, F. A. D. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7002e1 · Cited by 479
Shimabukuro, T. T., Cole, M., & Su, J. R. (2021) · JAMA · doi:10.1001/jama.2021.1967 · Cited by 475
Self-citationDooling, K., Marin, M., Wallace, M., McClung, N., Chamberland, M., Lee, G. M., Talbot, H. K., Romero, J. R., Bell, B. P., & Oliver, S. E. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm695152e2 · Cited by 406
Pottegård, A., Lund, L. C., Karlstad, Ø., Dahl, J., Andersen, M., Hallas, J., Lidegaard, Ø., Tapia, G., Gulseth, H. L., Ruiz, P. L.-D., et al. (2021) · BMJ · doi:10.1136/bmj.n1114 · Cited by 401
Gee, J., Marquez, P., Su, J., Calvert, G. M., Liu, R., Myers, T., Nair, N., Martin, S., Clark, T., Markowitz, L., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7008e3 · Cited by 395
Self-citationRüggeberg, J. U., Gold, M. S., Bayas, J.-M., Blum, M. D., Bonhoeffer, J., Friedlander, S., de Souza Brito, G., Heininger, U., Imoukhuede, B., Khamesipour, A., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.064 · Cited by 383
Risk of anaphylaxis after vaccination in children and adults.
McNeil, M. M., Weintraub, E. S., Duffy, J., Sukumaran, L., Jacobsen, S. J., Klein, N. P., Hambidge, S. J., Lee, G. M., Jackson, L. A., Irving, S. A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.07.048 · Cited by 381
Self-citationSymptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination
Marshall, M., Ferguson, I. D., Lewis, P., Jaggi, P., Gagliardo, C., Collins, J. S., Shaughnessy, R., Caron, R., Fuss, C., Corbin, K. J. E., et al. (2021) · Pediatrics · doi:10.1542/peds.2021-052478 · Cited by 367
The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety
Baggs, J., Gee, J., Lewis, E., Fowler, G., Benson, P., Lieu, T., Naleway, A., Klein, N. P., Baxter, R., Belongia, E., et al. (2011) · Pediatrics · doi:10.1542/peds.2010-1722h · Cited by 349
Self-citationOliver, S. E., Gargano, J. W., Marin, M., Wallace, M., Curran, K. G., Chamberland, M., McClung, N., Campos-Outcalt, D., Morgan, R. L., Mbaeyi, S., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm695152e1 · Cited by 317
Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures
Klein, N. P., Fireman, B., Yih, W. K., Lewis, E., Kulldorff, M., Ray, P., Baxter, R., Hambidge, S., Nordin, J., Naleway, A., et al. (2010) · Pediatrics · doi:10.1542/peds.2010-0665 · Cited by 316
Self-citationAcute Allergic Reactions to mRNA COVID-19 Vaccines
Blumenthal, K. G., Robinson, L. B., Camargo, C. A., Shenoy, E. S., Banerji, A., Landman, A. B., & Wickner, P. (2021) · JAMA · doi:10.1001/jama.2021.3976 · Cited by 275
Risk of Intussusception after Monovalent Rotavirus Vaccination
Weintraub, E. S., Baggs, J., Duffy, J., Vellozzi, C., Belongia, E. A., Irving, S., Klein, N. P., Glanz, J. M., Jacobsen, S. J., Naleway, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311738 · Cited by 223
Self-citationReal-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events
Lieu, T. A., Kulldorff, M., Davis, R. L., Lewis, E. M., Weintraub, E., Yih, K., Yin, R., Brown, J. S., & Platt, R. (2007) · Medical Care · doi:10.1097/mlr.0b013e3180616c0a · Cited by 221
Self-citationBell's palsy and SARS-CoV-2 vaccines
Ozonoff, A., Nanishi, E., & Levy, O. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00076-1 · Cited by 158
In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine
Muthukumar, A., Narasimhan, M., Li, Q., Mahimainathan, L., Hitto, I., Fuda, F. S., Batra, K., Jiang, X., Zhu, C., Schoggins, J. W., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056038 · Cited by 135
H1N1 and Seasonal Influenza Vaccine Safety in the Vaccine Safety Datalink Project
Lee, G. M., Greene, S. K., Weintraub, E., Baggs, J. M., Kulldorff, M., FIREMAN, B. H., Baxter, R. P., Jacobsen, S. J., Irving, S. A., Daley, M. F., et al. (2011) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.04.004 · Cited by 130
Self-citationRenoud, L., Khouri, C., Revol, B., Lepelley, M., Perez, J., Roustit, M., & Cracowski, J. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2219 · Cited by 122
Sex and Gender Aspects for Patient Stratification in Allergy Prevention and Treatment
Martinis, M. D., Sirufo, M. M., Suppa, M., Silvestre, D. D., & Ginaldi, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041535 · Cited by 112
Developing a SARS-CoV-2 Vaccine at Warp Speed
O’Callaghan, K. P., Blatz, A. M., & Offit, P. A. (2020) · JAMA · doi:10.1001/jama.2020.12190 · Cited by 82
Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine
Donahue, J. G., Kieke, B. A., Lewis, E. M., Weintraub, E., Hanson, K. E., McClure, D. L., Vickers, E. R., Gee, J. M., Daley, M. F., Destefano, F. R., et al. (2019) · PEDIATRICS · doi:10.1542/peds.2019-1808 · Cited by 48
Self-citationYoon, P. W., Hall, J. E., Fuld, J., Mattocks, S. L., Lyons, B. C., Bhatkoti, R., Henley, J., McNaghten, A. D., Daskalakis, D., & Pillai, S. K. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7032a2 · Cited by 48
Pingali, C., Meghani, M., Razzaghi, H., Lamias, M. J., Weintraub, E., Kenigsberg, T. A., Klein, N. P., Lewis, N., FIREMAN, B. H., Zerbo, O., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7028a1 · Cited by 45
Self-citationSex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines
Somiya, M., Mine, S., Yasukawa, K., & Ikeda, S. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.04.066 · Cited by 32
Cited by
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., Watkinson, P., Khunti, K., Harnden, A., Coupland, C. A. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01630-0 · Cited by 637
Epidemiology and prevention of venous thromboembolism
Lutsey, P. L., & Zakai, N. A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00787-6 · Cited by 507
Covid-19 Vaccines — Immunity, Variants, Boosters
Barouch, D. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2206573 · Cited by 442
Metadata
- Authors
- Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., Donahue, J. G., Kharbanda, E. O., Naleway, A., Nelson, J. C., Xu, S., Yih, W. K., Glanz, J. M., Williams, J. T. B., Hambidge, S. J., Lewin, B. J., Shimabukuro, T. T., DeStefano, F., & Weintraub, E. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-10-12
- Volume
- 326
- Issue
- 14
- Pages
- 1390
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3197830587
- Cited by
- 626
- References
- 32
- FWCI
- 38.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.